Avoro Capital Advisors LLC
Q3 2021 13F-HR Holdings
Net value change ($000)
+617,559
(10.7%)
New positions
6
Sold out positions
7
Turnover %
5.9%
Sector allocation + QoQ delta (equities-only)
Snapshot: Change Analysis
Compared to Q2 2021
Methodology:
sector metrics are equities-only;
instrument mix chart is ex-options;
options exposure is shown separately.
Why this matters.
Top Adds (Value $000, Stocks/ETFs)
| XLRN | 311,930 | 82.9% |
| Horizon Therapeutics Public Ltd Co | 143,100 | 17.0% |
| APLS | 101,269 | 159.4% |
| Mirati Therapeutics, Inc. | 76,900 | 9.5% |
| IVERIC bio, Inc. | 74,762 | 184.4% |
| ASND | 65,647 | 26.3% |
| WHWK | 53,730 | NEW |
| FOLD | 48,819 | 40.7% |
| Trillium Therapeutics Inc. | 44,802 | 81.0% |
| SRPT | 44,624 | 23.9% |
Top Reduces (Value $000, Stocks/ETFs)
| CONSTELLATION PHARMACEUTICALS INC | -108,498 | -100.0% |
| ARENA PHARMACEUTICALS INC | -73,956 | -26.6% |
| VRTX | -38,845 | -24.4% |
| RLMD | -29,929 | -100.0% |
| Mersana Therapeutics, Inc. | -28,220 | -30.6% |
| IOVA | -27,172 | -11.5% |
| MDGL | -25,108 | -18.1% |
| OLMA | -24,538 | -100.0% |
| ACAD | -23,010 | -38.6% |
| SNDX | -21,985 | -42.7% |
Instrument mix + QoQ Δ (ex-options)
Derivatives reported exposure ($000):
5,026
(0.1% of total reported value)
How this table is calculated:
SEC
VALUE ($000) is used as reported.
For derivatives (PUT/CALL/WARRANT/RIGHT), SEC value represents reported underlying exposure, not premium cash paid/received.
Column % is bucket-based:
non-options share is calculated inside non-option total, options share is calculated inside options total.
Details.
Filter:
Instrument:
| Issuer Name | Ticker | Sector | Industry | Class | History | Value ($000) | % | Shares | Shares Δ | Shares Δ% | Value Δ ($000) | Value Δ% | Principal | Option Type |
|---|